Liminatus Pharma, Inc. Class A Common Stock
LIMN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,685 | $3,757 | $1,853 | $3,802 |
| G&A Expenses | $645 | $1,062 | $856 | $197 |
| SG&A Expenses | $645 | $1,062 | $856 | $197 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$424 | -$2,233 | $0 | -$1,465 |
| Operating Expenses | $2,906 | $2,586 | $2,709 | $2,534 |
| Operating Income | -$2,906 | -$2,586 | -$2,709 | -$2,534 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $21 | $1,394 | -$219 | $6,904 |
| Pre-Tax Income | -$2,885 | -$1,192 | -$2,928 | $4,370 |
| Tax Expense | $19 | $34 | $0 | $0 |
| Net Income | -$2,904 | -$1,226 | -$2,928 | $4,370 |
| % Margin | – | – | – | – |
| EPS | -0.4 | -0.15 | -0.082 | 0.13 |
| % Growth | -166.7% | -82.3% | -163.3% | – |
| EPS Diluted | -0.4 | -0.15 | -0.082 | 0.13 |
| Weighted Avg Shares Out | 7,192 | 8,013 | 34,428 | 34,500 |
| Weighted Avg Shares Out Dil | 7,192 | 8,013 | 34,428 | 34,500 |
| Supplemental Information | – | – | – | – |
| Interest Income | $138 | $10 | $0 | $17 |
| Interest Expense | $138 | $175 | $219 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$2,747 | -$1,089 | -$2,709 | $4,370 |
| % Margin | – | – | – | – |